SEC Form 4 · accession 0000930413-18-002500
ENZO BIOCHEM INC · ENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elazar Rabbani
Officer — Chm of the Bd, CEO and Sec · Director
Period of report
Jul 31, 2018
Accepted (ET)
Aug 2, 2018 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000316253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (to acquire common stock)F1,F2 | $4.42 | Jul 31, 2018 | A | 90,000 | A | Aug 1, 2019 | Jul 31, 2023 | Common Stock | 90,000 | 184,749 | D |
Explanation of responses
- F1The Reporting Person was granted 90,000 stock options. The options have a five-year term and shall vest in two equal annual tranches, beginning August 1, 2019.
- F2Does not include 10,000 Performance Stock Units granted to the Reporting Person on July 31, 2018, which will vest, if at all, based upon (i) achievement of average revenue growth and adjusted EBITDA growth goals on July 31, 2021, and (ii) the continued service of the Reporting Person through July 31, 2021.